Monograph of Magnesium Hydroxide

Introduction

Magnesium hydroxide (Mg(OH)₂) is a white, crystalline salt widely employed as an antacid and osmotic laxative. Its unique physicochemical properties allow it to neutralize gastric acid rapidly while exerting minimal systemic absorption, thereby providing a safe therapeutic option for dyspepsia and constipation. Historically, the use of magnesium salts dates back to ancient civilizations, where mineral water rich in magnesium was consumed for digestive relief. Over the past century, magnesium hydroxide has been refined into standardized pharmaceutical formulations, enabling precise dosing and predictable pharmacodynamic responses.

Learning objectives for this chapter include:

• Understanding the chemical structure and solubility profile of magnesium hydroxide.
• Comprehending the pharmacokinetic principles governing its absorption, distribution, metabolism, and elimination.
• Recognizing the clinical indications, contraindications, and drug–drug interaction potential.
• Applying knowledge of magnesium hydroxide to case-based scenarios involving antacid and laxative therapy.
• Identifying safety considerations and monitoring parameters for patients receiving magnesium hydroxide.

Fundamental Principles

Core Concepts and Definitions

Magnesium hydroxide is an inorganic salt composed of divalent magnesium cations (Mg²⁺) and hydroxide anions (OH⁻). The compound exhibits low aqueous solubility (≈0.0003 g/100 mL at 25 °C) but dissolves readily in acidic environments, a property that underlies its antacid activity. In the gastrointestinal tract, Mg(OH)₂ reacts with hydrochloric acid (HCl) to yield soluble magnesium chloride (MgCl₂) and water, thereby buffering gastric pH.

Theoretical Foundations

The dissolution reaction can be represented as:

Mg(OH)₂ + 2 H⁺ → Mg²⁺ + 2 H₂O

Because the solubility product (K_sp) of Mg(OH)₂ is low, the equilibrium favors ion formation only in the presence of excess H⁺ ions. Consequently, magnesium hydroxide remains largely undissolved in neutral or alkaline environments, limiting systemic absorption. The pharmacokinetic profile is therefore characterized by a rapid, local action with negligible systemic exposure, as reflected by a bioavailability (F) of < 1 % in healthy volunteers.

Key Terminology

• Solubility product (K_sp): A quantitative measure of a compound’s tendency to dissolve in water.
• Bioavailability (F): The fraction of an administered dose that reaches systemic circulation unchanged.
• Half‑life (t_1/2): The time required for plasma concentration to reduce by 50 %.
• Clearance (CL): The volume of plasma from which the drug is completely removed per unit time.
• Area under the curve (AUC): The integral of plasma concentration over time, representing overall drug exposure.

Detailed Explanation

Physicochemical Properties

Magnesium hydroxide crystallizes in the hexagonal crystal system. Its density is 1.54 g/cm³, and it exhibits a characteristic low hygroscopicity, which reduces the risk of moisture-induced agglomeration during storage. The compound’s pKa is not directly relevant, as it is not a weak acid or base; however, its interaction with gastric acid is governed by the acidity of the environment (pH < 4). The low solubility ensures that only a small fraction dissolves in the stomach, limiting the amount of Mg²⁺ that can be absorbed.

Absorption and Distribution

Following oral administration, magnesium hydroxide remains largely in the gastrointestinal lumen. The amount of Mg²⁺ released is dependent on gastric acid concentration and transit time. Because systemic absorption is minimal, the plasma concentration of Mg²⁺ remains below toxic thresholds (≈1.5 mmol/L) in standard therapeutic doses. Distribution is largely confined to extracellular fluid, and the compound does not cross the blood–brain barrier. In patients with impaired renal function or altered gastric pH, absorption may increase modestly, necessitating dose adjustment.

Pharmacokinetic Models

When a dose (D) of magnesium hydroxide is administered, the concentration of dissolved magnesium in plasma can be approximated by a first‑order absorption model:

C(t) = (F × D / V_d) × e^-k_el t

where V_d is the apparent volume of distribution and k_el is the elimination rate constant. Because F is low, the peak concentration (C_max) is typically < 0.05 mg/mL. Elimination proceeds primarily via renal excretion of Mg²⁺, with a half‑life of approximately 1–2 hours in healthy adults. The overall exposure (AUC) can be expressed as:

AUC = (F × D) ÷ CL

Given the small F, AUC values remain clinically insignificant when standard doses are used.

Factors Influencing Pharmacodynamics

• Gastric pH: Lower pH enhances dissolution; achlorhydria reduces efficacy.
• Meal Composition: High-fat meals may delay gastric emptying, prolonging contact time and potentially increasing Mg²⁺ release.
• Renal Function: Reduced glomerular filtration rate (GFR) can lead to accumulation of Mg²⁺; monitoring serum magnesium is advised.
• Co‑administered Drugs: Agents that alter gastric pH (e.g., proton pump inhibitors) or compete for renal excretion (e.g., diuretics) may modify magnesium levels.

Clinical Significance

Antacid Use

Magnesium hydroxide’s ability to neutralize gastric acid makes it a first‑line agent for acute heartburn, gastroesophageal reflux disease (GERD), and peptic ulcer discomfort. The neutralization reaction raises intragastric pH, providing symptomatic relief within minutes. Because of its minimal systemic absorption, it is preferred over cationic antacids in patients requiring long‑term therapy or those at risk of hypocalcemia.

Laxative Effect

When administered in larger doses, magnesium hydroxide exerts an osmotic effect, drawing water into the colon and stimulating peristalsis. The typical laxative dose is 10–20 g of magnesium hydroxide per day, which can be divided into two or three administrations. The onset of action is usually 30–60 minutes, and complete evacuation may occur within 24 hours. This property is utilized in the treatment of acute constipation, bowel preparation before endoscopy, and as a supplemental therapy in chronic constipation management.

Drug–Drug Interactions

Magnesium hydroxide may interfere with the absorption of drugs that are weak bases, such as ketoconazole, phenytoin, and tetracyclines. The binding of magnesium ions in the gastrointestinal tract can alter the ionization state of these medications, reducing their bioavailability. Consequently, a temporal separation of at least 2 hours between magnesium hydroxide and these agents is recommended. Conversely, magnesium hydroxide can mitigate the gastrointestinal irritation caused by non‑steroidal anti‑inflammatory drugs (NSAIDs) by buffering gastric acid.

Safety and Toxicity

Systemic toxicity is rare with therapeutic dosing. However, in patients with severe renal impairment, hypermagnesemia may develop, manifesting as hypotension, hyporeflexia, and respiratory depression. Monitoring serum magnesium levels is advised in high‑dose or prolonged use. Overdose may lead to a loss of bowel sounds, decreased cardiac contractility, and in extreme cases, cardiac arrest. The lethal dose in adults is estimated at >15 g taken orally, although fatalities are uncommon due to the compound’s low absorption.

Clinical Applications/Examples

Case Scenario 1: Acute Heartburn in a Healthy Adult

A 35‑year‑old female presents with post‑prandial epigastric discomfort. She reports mild nausea but no vomiting or weight loss. Physical examination is unremarkable. Standard therapy would involve a single dose of 500 mg magnesium hydroxide, which has been shown to achieve symptomatic relief in 80 % of patients within 30 minutes. The patient is advised to avoid additional antacids for 4 hours to prevent overlapping neutralization effects.

Case Scenario 2: Chronic Constipation in a Patient with Renal Insufficiency

A 68‑year‑old male with chronic kidney disease stage 3 (GFR 30 mL/min) experiences intermittent constipation. A low‑dose magnesium hydroxide regimen (5 g per day divided into two doses) is initiated, with serum magnesium monitored monthly. The patient reports improved stool frequency without significant changes in serum magnesium, supporting the safety of cautious dosing in renal impairment.

Case Scenario 3: Laxative Preparation Before Colonoscopy

Prior to a colonoscopy, a 45‑year‑old female receives a bowel cleansing protocol comprising polyethylene glycol (PEG) solution and 10 g magnesium hydroxide. The magnesium hydroxide serves to accelerate colonic transit, ensuring adequate cleansing. The patient tolerates the regimen well, with no adverse events reported.

Problem‑Solving Approach to Drug–Drug Interaction

1. Identify the medication that may be affected by magnesium hydroxide (e.g., tetracycline).
2. Determine the absorption window for the affected drug (typically 1–2 hours post‑dose).
3. Schedule magnesium hydroxide administration at least 2 hours before or after the affected drug.
4. Reassess therapeutic response after adjustment.

Summary / Key Points

• Magnesium hydroxide is a low‑solubility, inorganic salt that neutralizes gastric acid via the reaction Mg(OH)₂ + 2 H⁺ → Mg²⁺ + 2 H₂O.
• Its pharmacokinetic profile is characterized by minimal systemic absorption (F < 1 %) and rapid elimination (t_1/2 ≈ 1–2 hours).
• Clinical indications include acute heartburn, GERD, and osmotic laxation for constipation and bowel preparation.
• Drug interactions arise primarily through reduced absorption of weak bases; temporal separation of ≥2 hours is advisable.
• Safety monitoring is essential in patients with renal impairment; serum magnesium should be checked when high or prolonged doses are used.
• Key pharmacokinetic relationships: C(t) = (F × D / V_d) × e^-k_el t; AUC = (F × D) ÷ CL.

Magnesium hydroxide remains a cornerstone in the pharmacologic management of gastrointestinal disorders due to its favorable safety profile, rapid onset of action, and dual therapeutic roles as an antacid and osmotic laxative. Continued vigilance regarding renal function, drug interactions, and patient education will ensure optimal therapeutic outcomes for medical and pharmacy students preparing to implement evidence‑based care.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.